title: [Second primary malignancy after surgical adjuvant therapy for gastric cancer].
abstract: Immunopotentiators are expected to intensify the effects of chemotherapy, but anticancer agents are in greater or lesser degree carcinogenic in humans. The carcinogenic risk after adjuvant chemo-immunotherapy was examined in 786 gastric cancer patients who underwent curative gastrectomy between 1963 and 1981. They consisted of 420 patients without any chemo- or immunotherapy (cont group), 302 with chemotherapy (chem group) with mitomycin C and/or fluorinated pyrimidines, and 64 with chemo-immunotherapy (chem-immu group) with both chemotherapy and immuno-potentiator (s), levamisole or PSK and/or OK-432. The incidence of cancers other than gastric cancer 5 or more years after gastrectomy was 9 out of 64 in the chem-immu group (14.1%), which was higher than the 25 out of 302 in the chem group (8.3%) and significantly higher than the 27 out of 420 in the cont group (6.4%) (p < 0.05). The 5/10-year survival rate after gastrectomy was 76.0%/72.5% in the chem-immu group, which was significantly higher than the 66.1% /59.4% in the chem group and the 64.7%/59.3% in the cont group (p < 0.05). Among 215 patients under 50 years of age, the survival rate was 72.7%/65.6% in the chem group, which was significantly lower than the 75.0%/71.7% in the cont group (p < 0.01) and lower than the 81.9%/81.9% in the chem-immu group. However, the incidence of a second malignancy showed a tendency to increase in the order of the cont, chem and chem-immu groups.
authors.affiliation: Dept. of Surgery and Clinical Oncology, Graduate School of Medicine, Osaka University, Japan.
authors.forename: J
authors.initials: J
authors.lastname: Fujimoto
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant; D005260:Female; D005500:Follow-Up Studies; D005743:Gastrectomy; D006801:Humans; D007167:Immunotherapy; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D016609:Neoplasms, Second Primary / Q000453:epidemiology* / Q000401:mortality; D011184:Postoperative Period; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000601:surgery; D015996:Survival Rate